PASADENA, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- InvisiDerm Healthcare (“InvisiDerm”), developer and manufacturer of noninvasive gas and drug delivery methods, announced the completion of the initial clinical study using its innovative D`Oxyva® transdermal delivery platform. The company has submitted the results to a peer-reviewed medical journal for publication in Q1 2013.
